This phase II trial is designed to investigate the effectiveness of Tarceva (OSI-774)
combined with capecitabine in treating patients with metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Massachusetts General Hospital Roche Global Development